FASN and prostate neoplasm: Zadra et al. reported that the AMPK activator MT63-78 decreased prostate tumor growth and inhibited FASN expression, and its antigrowth effects were mediated by the inhibition of lipogenesis in androgen-sensitive and castration-resistant models [25].